Skip to Content
Contact DCTD
Show menu
Search this site
Last Updated: 10/18/2019

DCTD’s Translational Research Program Announces Fiscal Year 2019 SPORE Grantees

The Translational Research Program (TRP) announced its successfully competed FY2019 Specialized Programs of Research Excellence (SPORE) grantees. The SPORE program uses the P50 and U54 grant funding mechanisms to promote collaborative, interdisciplinary, translational cancer multi-project research. SPOREs are primarily focused on organ site disease, but also on themes that cut across organ sites. Including the 2019 grantees, there are now 54 SPOREs located at academic centers in 20 states.

FY 2019 SPORE Grantees

Principal Investigator Institution Cancer Type
*Tracy T. Batchelor Brigham and Women’s Hospital Brain
*Eric P. Winer Dana-Farber Cancer Institute Breast
*Adam Joel Bass and Nabeel El-Bardeesy  Dana-Farber Cancer Institute Gastrointestinal
*Kenneth Anderson and Nikhil C. Munshi Dana-Farber Cancer Institute Myeloma
*John H. Sampson and Francis Ali-Osman Duke University Brain
Suresh S. Ramalingam and Haian Fu Emory University Lung
McGarry A. Houghton Fred Hutchinson Cancer Research Center Lung
*Tzyy-Choou Wu Johns Hopkins University Cervical
Iman Osman and Jeffrey S. Weber New York University Skin
*Robert E. Reiter University of California, Los Angeles Prostate
*Arul M. Chinnaiyan, Elisabeth Iljas Heath, and Ganesh S. Palapattu University of Michigan, Ann Arbor Prostate
*Frederick F. Lang and Juan Fueyo University of Texas MD Anderson Brain
Scott Kopetz and Anirban Maitra  University of Texas MD Anderson Gastrointestinal
Laura Beretta and Ahmed Kaseb University of Texas MD Anderson Liver
Patrick Hwu University of Texas MD Anderson Skin
*Jennifer A. Pietenpol and Ingrid A. Mayer Vanderbilt University Medical Center Breast
Robert J. Coffey Vanderbilt University Medical Center Gastrointestinal

*Grant Renewal

The goals of the SPORE program include:

  • Translating novel scientific discoveries from the laboratory and/or population studies to the clinic for testing in humans with cancer or at risk for cancer
  • Determining the biological basis for clinical observations
  • Using specimens from clinical studies to determine correlations between biomarkers and outcomes in patients
  • Promoting collaborations between SPOREs, Cancer Centers, other NCI/NIH funded mechanisms and programs, and outside organizations
  • Promoting pilot projects and career enhancement of researchers new to translational research
  • Supporting research in high incidence and rare cancers
  • Encouraging communication with advocates and advocate organizations to obtain advice from the patient perspective

Contact TRP staff for more information on the SPORE program.